Rain Enhancement Technologies Holdco Inc
Rain Enhancement Technologies Holdco Inc Q2 FY2023 earnings call
August 10, 2023 · fiscal period ended 2023-06
EPS · actual vs est
Revenue · actual vs est
Summary
Generated 2023-08-10
Management highlights
- Rain reported that the Phase 3 global registrational trial for milademetan in dedifferentiated liposarcoma did not meet the primary endpoint. - Suspended enrollment of the MANTRA-2 study and began closing it down. - Plan to present final data from the MANTRA Phase 3 study and updated data from the MANTRA-2 Phase 2 study in Q4 2023. - Implemented cost-saving measures including workforce reduction to moderate cash burn. - Corporate development team reviewing opportunities to license or acquire clinical stage programs and technologies across small molecule and large molecule approaches.
Segment performance
Rain Oncology reported a net loss of $22.1 million for the three months ended June 30, 2023, compared to a net loss of $17.6 million in the same period in 2022. General and administrative expenses were $5.4 million for Q2 2023 vs. $3.5 million in Q2 2022. Restructuring charges of $2.8 million were recorded in Q2 2023. As of June 30, 2023, Rain had $86.3 million in cash, cash equivalents, and short-term investments.
Guidance
- Rain anticipates quarter-end cash position will provide runway into year-end 2026 in absence of corporate transaction and partner financing. - Significant reduction in cash burn expected in Q3 and beyond.
Q&A highlights
Q: Potential new opportunities and modality interest?
A: Avanish Vellanki said they're opportunistic across precision oncology strategies, both small molecule and large molecule.
Q: Future of milademetan and RAD52 program?
A: Avanish Vellanki said no plans for milademetan currently and RAD52 program is not being moved forward.
Q: Cash burn guidance and SG&A/R&D?
A: Nelson Cabatuan said cash burn in Q3 onwards will be significantly lower than prior quarters.
Q: Reasons for milademetan underperformance?
A: Robert Doebele said to refer to upcoming Q4 presentations.
Q: Sweet spot for licensing deals?
A: Avanish Vellanki said looking for clinical stages to leverage their clinical organization.
Q: Weighing new asset vs corporate options?
A: Avanish Vellanki said looking at attractiveness and actionability of opportunities.
Q: Technology platform and licensing limits?
A: Avanish Vellanki said will provide details when appropriate.
Key numbers
Reported versus consensus
Earnings calendar feed
| Metric | Reported | Consensus | Delta | Prior year |
|---|---|---|---|---|
| EPS | $-0.61 | $-0.49 | -24.5% | — |
| Revenue | — | — | — | — |
Transcript
August 10, 2023Full transcript unavailable for redistribution
The structured summary above covers the available call sections. Full transcript text is not included on this page.
Continue exploring
Prior quarters
This page presents the stored structured earnings-call summary and deterministic earnings calendar values. How this is generated. For informational purposes only; not investment advice.